WO2026093896 - TREATMENT OF MULTIPLE SCLEROSIS USING A POPULATION OF CD19 CAR-EXPRESSING CELLS
National phase entry is expected:
Publication Number
WO/2026/093896
Publication Date
07.05.2026
International Application No.
PCT/IB2025/060938
International Filing Date
27.10.2025
Title **
[English]
TREATMENT OF MULTIPLE SCLEROSIS USING A POPULATION OF CD19 CAR-EXPRESSING CELLS
[French]
TRAITEMENT DE LA SCLÉROSE EN PLAQUES À L'AIDE D'UNE POPULATION DE CELLULES EXPRIMANT UN CAR ANTI-CD19
Applicants **
NOVARTIS AG
Inventors
ADIWIJAYA, Bambang
AWASTHI, Rakesh
PEARSON, David Scott
STANGEL, Martin
Priority Data
63/712,684
28.10.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4607 | |
| EPO | Filing, Examination, Granting | 77330 | |
| Japan | Filing, Examination, Granting | 4501 | |
| South Korea | Filing, Examination, Granting | 6469 | |
| USA | Filing, Examination, Granting | 25540 |
Total:
118,447
Contact Us
Abstract[English]
The invention provides methods of using a population of CD19 CAR-expressing cells (for example, rapcabtagene autoleucel) for treating neuroimmune diseases or disorders. Also disclosed are methods of making a population of CD19 CAR-expressing cells.[French]
L'invention concerne des méthodes d'utilisation d'une population de cellules exprimant un CAR anti-CD19 (par exemple, rapcabtagène autoleucel) pour traiter des maladies ou troubles neuro-immuns. Sont également divulgués des procédés de fabrication d'une population de cellules exprimant un CAR anti-CD19.